Plain-English translation of NCT05340491 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 3 โ Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether adding an anti-PD-1 antibody โ a medication that helps your immune system fight cancer โ to standard and radiation therapy works better than and radiation alone for people with recurrent nasopharyngeal cancer. About 212 patients will be randomly assigned to receive either the combination treatment or standard treatment alone. The trial will measure how well the treatment works and what side effects occur.
Nasopharyngeal cancer that comes back after initial treatment is difficult to manage, and outcomes for these patients remain poor. Researchers believe that adding this immune-boosting medication might help the body better recognize and destroy remaining cancer cells.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
If you enroll, you will be randomly assigned to one of two groups. Both groups will receive three rounds of followed by radiation therapy. The group receiving the new treatment will also receive the anti-PD-1 antibody during and then continue receiving it for eight more cycles after radiation as maintenance therapy. You will have regular clinic visits to monitor your health, check how well the treatment is working, and watch for side effects. The trial is being conducted at multiple hospitals across China.
AI-generated summary from trial data ยท Jul 15, 2026 ยท Not medical advice
China